Journal
CELL METABOLISM
Volume 31, Issue 6, Pages 1068-+Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2020.04.021
Keywords
-
Categories
Funding
- National Key RAMP
- D Program of China [2016YFF0101504]
- National Natural Science Foundation of China [81630011, 81970364, 81970070, 81970011, 81870171]
- Major Research Plan of the National Natural Science Foundation of China [91639304]
- Hubei Science and Technology Support Project [2019BFC582, 2018BEC473, 2017BEC001]
- Medical Flight Plan of Wuhan University
Ask authors/readers for more resources
Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available